|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to analyze the value of immunostaining for p16 in the morphologic assessment of cervical intraepithelial neoplasia 2 lesions, to help differentiate between low-grade (p16-negative) and high-grade (p16-positive) squamous intraepithelial lesions.
|
29734247 |
2019 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association between oropharyngeal cancers with known HPV and p16 status and cervical intraepithelial neoplasia: a Danish population-based study.
|
30626248 |
2019 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies were selected if they included women with ASC-US or LSIL who were triaged with dual staining (p16/Ki-67) and/or p16 staining and, if available, with a comparator hrHPV test to detect cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) or CIN3+.
|
30811902 |
2019 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of the assessment of HPV DNA load with the intensity of p16 and Ki-67 staining could increase the sensitivity of CIN lesion diagnosis and predict the outcome of CIN2 in patients with a HPV-16 and/or 58 infection.
|
31619262 |
2019 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cervical intraepithelial neoplasia (CIN) 2 is an equivocal diagnosis, with p16 immunohistochemical positivity currently recommended for diagnostic confirmation.
|
29438168 |
2018 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A strong statistical significance was assessed correlating LSIL/HSIL cases with a progressive p16 over expression (p=0.001), also reflecting a higher CIN diagnosis (p=0.001).
|
30275203 |
2018 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the CERvical Tissue AdjunctIve aNalysis (CERTAIN) study, we systematically analyzed the impact of adjunctive p16 IHC on the accuracy (agreement with reference pathology results) of diagnosing cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) in the United States.
|
29697437 |
2018 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The addition of p16-mRNA assay to visual reading of p16 IHC improved the AUC from 0.77 to 0.84 (p = 0.0049). p16-mRNA testing may be complementary to visual IHC p16 staining for a more accurate diagnosis of CIN, or perhaps a substitute in locations with a lack of skilled pathologists.
|
28509346 |
2017 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the association between p16 immunostaining and CIN grade was significant in non-pregnant patients but not in pregnant patients.
|
28123559 |
2017 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, the methylation status of three tumor suppressor genes, retinoic acid receptor β (RARβ), p16 and cadherin 1 (CDH1), and the inflammatory-associated cyclooxygenase-2 (COX-2) gene, was examined at distinct stages of cervical intraepithelial neoplasia (CIN).
|
28599442 |
2017 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we compared HPV genotypes and subsequent high-grade squamous intraepithelial lesion (HSIL) outcomes among 220 cervical biopsies with a differential diagnosis of cervical intraepithelial neoplasia 2 based on hematoxylin and eosin morphology and varying degrees of p16 immunoreactivity. p16 results were classified as block positive (n=40, 18%), negative (n=130, 59%), or ambiguous (n=50, 23%), a category we further grouped into 3 patterns: strong/basal (n=18), strong/focal (n=15), and weak/diffuse (n=17).
|
28705710 |
2017 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study evaluated p16 expression in women with a histological diagnosis of cervical intraepithelial neoplasia (CIN) 3 or higher and correlated this expression with HPV genotypes to determine possible discrepancies in the expression of this marker.
|
27706717 |
2016 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation frequency of P16 and RBSP3 in basal-parabasal layers of normal did not change significantly in CIN and CACX.
|
27458253 |
2016 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the sensitivity and specificity of p16 immunostaining in detection of underlying HG lesions was evaluated in a cohort of 454 women undergoing surgical treatment for biopsy proven cervical dysplasia.
|
25938364 |
2015 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HPV-16 or -18 were present in 59.7% (80/134) of abnormal specimens. p16 and E6 mRNA expression was increasing with severity of cervical dysplasia. p16 mRNA expression was found 4.35-fold and 13.15-fold increased in high-grade squamous intraepithelial lesions and squamous cell carcinomas, respectively.
|
24477172 |
2014 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, high-risk HPV E6/E7 and p16 mRNA expression patterns in eighty-six CIN lesions were investigated by RNAscope chromogenic in situ hybridization (CISH).
|
24625757 |
2014 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we studied the immunohistochemical expression of p16 in 86 dysplastic cervical lesions, 54 cervical intraepithelial neoplasms-grade 1 (CIN-I), 23 CIN-II, and 9 CIN-III.
|
24656093 |
2014 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, data are insufficient to determine whether p16 overexpression predicts the risk for progression of low-grade cervical intraepithelial neoplasia (CIN).
|
24172101 |
2013 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the relation between p16 status and risk of CIN during 3 years of follow-up.
|
23261355 |
2013 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared the efficacy of p16 and ProExC immunostaining in detecting cervical intraepithelial neoplasia (CIN) 2+ in 136 formalin-fixed, paraffin-embedded cervical tissue specimens with consensus diagnoses of normal cervix, CIN 1, CIN 2, CIN 3, and carcinoma.
|
21228361 |
2011 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fragile histidine triad (FHIT), E-cadherin, Rb, Ki-67, and p16 expression was significantly increased in HPV-positive tissue by increasing CIN grade.
|
21558960 |
2011 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, there is no consensus on whether methylation of the p16 gene could be used as a biomarker in cervical intraepithelial neoplasia.
|
20186007 |
2010 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of the P16 protein has been reported in cervical intraepithelial neoplasia (CIN) as well as cervical cancer.
|
18936966 |
2008 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There were no statistically significant differences in p16 expression between CIN and condyloma acuminatum samples.
|
17488337 |
2007 |
|
Cervical Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women seen at Pérola Byington Hospital, São Paulo, Brazil, with histologically confirmed cervicitis (n = 31), cervical intraepithelial neoplasia (CIN) 1 (n = 30), CIN 2,3 (n = 30), and cervical cancer (n = 7) had also cervical material collected for liquid-based cytology, human papillomavirus Hybrid Capture 2 (HC2) test, and p16 and FHIT immunohistochemical reactions.
|
17596760 |
2007 |